Evidence map›Paper›PMID 34960187›Full record

ArticleVaccines2021

Update on the Inactivation Procedures for the Vaccine Development Prospects of a New Highly Virulent RGNNV Isolate.

Alberto Falco, Melissa Bello-Perez, Rocío Díaz-Puertas, Matthew Mold, Mikolaj Adamek

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Alberto FalcoInstitute of Research, Development and Innovation in Healthcare Biotechnology in Elche (IDiBE), Miguel Hernández University, 03202 Elche, Spain.ORCID 0000-0001-7726-6577
Melissa Bello-PerezInstitute of Research, Development and Innovation in Healthcare Biotechnology in Elche (IDiBE), Miguel Hernández University, 03202 Elche, Spain.
Rocío Díaz-PuertasInstitute of Research, Development and Innovation in Healthcare Biotechnology in Elche (IDiBE), Miguel Hernández University, 03202 Elche, Spain.
Matthew MoldThe Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire ST5 5BG, UK.ORCID 0000-0002-4616-6204
Mikolaj AdamekFish Disease Research Unit, Institute for Parasitology, University of Veterinary Medicine, 30559 Hannover, Germany.ORCID 0000-0003-4890-3164
Universitat de Miguel Hernández d'Elx · ESKeele University · GBUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

Spanish Ministry of Economy and Competitiveness RTI2018-101969-J-I00
6 · The paper itself

Abstract

Viral nervous necrosis (VNN) caused by the nervous necrosis virus (NNV) affects a broad range of primarily marine fish species, with mass mortality rates often seen among larvae and juveniles. Its genetic diversification may hinder the effective implementation of preventive measures such as vaccines. The present study describes different inactivation procedures for developing an inactivated vaccine against a new NNV isolate confirmed to possess deadly effects upon the European seabass (

Indexed as

autogenous vaccinebetanodavirusnervous necrosis virusviral nervous necrosisvirus-inactivated vaccinevirus inactivation

Identifiers

PMID34960187
PMCPMC8705346
OpenAlexW4200113612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.